ACTRIMS: Pioneering Research and Treatment in Multiple Sclerosis

Since its inception in 1995, the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has been at the forefront of advancing research and treatment options for Multiple Sclerosis (MS) and other demyelinating diseases. As a community of esteemed leaders from the United States and Canada, ACTRIMS is dedicated to improving the lives of individuals affected by these debilitating conditions.

Fostering Collaboration and Education

ACTRIMS’ primary objective is to facilitate knowledge dissemination, education, and interdisciplinary collaboration among top researchers, clinicians, and healthcare professionals. By bridging the gap between research and treatment, ACTRIMS aims to accelerate breakthroughs in MS research and improve patient outcomes.

Programs and Initiatives

ACTRIMS offers a range of programs and initiatives designed to promote innovation, enhance patient care, and advance our understanding of MS and demyelinating diseases. Learn more about our programs and initiatives and how they are shaping the future of MS research and treatment.